At the time of writing, Bristol-Myers Squibb Co [BMY] stock is trading at $56.84, down -1.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BMY shares have gain 0.34% over the last week, with a monthly amount glided 0.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bristol-Myers Squibb Co [NYSE: BMY] stock has seen the most recent analyst activity on December 16, 2024, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $70 for it. On November 15, 2024, Wolfe Research initiated with a Peer Perform rating. Daiwa Securities upgraded its rating to a Outperform. Leerink Partners upgraded its rating to a Outperform but $73 remained the price target by the analyst firm on November 12, 2024. Citigroup downgraded its rating to Neutral for this stock on October 25, 2024, and downed its price target to $55. In a note dated October 17, 2024, Bernstein initiated an Mkt Perform rating and provided a target price of $56 on this stock.
For the past year, the stock price of Bristol-Myers Squibb Co fluctuated between $39.35 and $61.08. Currently, Wall Street analysts expect the stock to reach $50.5 within the next 12 months. Bristol-Myers Squibb Co [NYSE: BMY] shares were valued at $56.84 at the most recent close of the market. An investor can expect a potential drop of -11.15% based on the average BMY price forecast.
Analyzing the BMY fundamentals
According to Bristol-Myers Squibb Co [NYSE:BMY], the company’s sales were 47.44B for trailing twelve months, which represents an 8.44% jump. Gross Profit Margin for this corporation currently stands at 0.7% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.36 and Total Capital is 0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.23 points at the first support level, and at 55.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.00, and for the 2nd resistance point, it is at 59.16.
Ratios To Look Out For
It is important to note that Bristol-Myers Squibb Co [NYSE:BMY] has a current ratio of 1.24. Also, the Quick Ratio is 1.09, while the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 2.43, the price to book ratio is 6.72.
Transactions by insiders
Recent insider trading involved Holzer Phil M, SVP and Controller, that happened on Nov 04 ’24 when 700.0 shares were sold. EVP,Chief Med.Offr.,Drug Dev., Hirawat Samit completed a deal on Nov 01 ’24 to buy 1830.0 shares. Meanwhile, Officer Holzer Phil M bought 700.0 shares on Nov 04 ’24.
